Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29791768
Publication Date : //

Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.


Immunological checkpoint blockade therapies benefit a limited population of cancer patients. We have previously shown that vaccine immunotherapy with Toll-like receptor (TLR)3-adjuvant and tumor antigen overcomes anti-programmed death ligand-1 (PD-L1) resistance in mouse tumor models. In the present study, 4 different ovalbumin (OVA)-expressing tumor cell lines were implanted into syngeneic mice and subjected to anti-tumor immunotherapy using ARNAX and whole OVA protein. ARNAX is a TLR3-specific agonist that does not activate the mitochondrial antiviral-signaling protein (MAVS) pathway, and thus does not induce systemic inflammation. Dendritic cell priming and proliferative CTL were induced by ARNAX + OVA, but complete remission was achieved only in a PD-L1-low cell line of EG7. Addition of anti-PD-L1 antibody to the ARNAX + OVA therapy brought complete remission to another PD-L1-high subline of EG7. Tumor shrinkage but not remission was observed in MO5 in that regimen. We analyzed tumor cells and tumor-infiltrating immune cells to identify factors associated with successful ARNAX vaccine therapy. Tumors that responded to ARNAX therapy expressed high levels of MHC class I and low levels of PD-L1. The tumor-infiltrating immune cells in ARNAX-susceptible tumors contained fewer immunosuppressive myeloid cells with low PD-L1 expression. Combination with anti-PD-L1 antibody functioned not only within tumor sites but also within lymphoid tissues, augmenting the therapeutic efficacy of the ARNAX vaccine. Notably, ARNAX therapy induced memory CD8 T cells and rejection of reimplanted tumors. Thus, ARNAX vaccine + anti-PD-L1 therapy enabled permanent remission against some tumors that stably present antigens.

Authors : Takeda Yohei , Yoshida Sumito , Takashima Ken , Ishii-Mugikura Noriko , Shime Hiroaki , Seya Tsukasa , Matsumoto Misako ,

Related products :

Catalog number Product name Quantity
31-018 TNFSF10 is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal ce 0.05 mg
31-024 TP53 acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activat 0.1 mg
29-012 SART3 is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in ca 0.1 mg
UB-E21550 Mouse Tumor Specific Growth Facter per tumor supplied group of factor(TSGF)ELISA Kit 96T
E0541Mo Mouse Tumor Specific Growth Facter per tumor supplied group of factor(TSGF)ELISA Kit 48T
H9547 Tumor Specific Growth Facter tumor supplied group of factor, TSGF, Mouse, ELISA Kit 96T
E0541Mo Mouse Tumor Specific Growth Facter-tumor supplied group of factor(TSGF)ELISA Kit 96T
SL0549Mo Mouse Tumor Specific Growth Facter tumor supplied group of factor,TSGF ELISA Kit 96T
YHB1365Mo Mouse Tumor Specific Growth Facter-tumor supplied group of factor(TSGF)ELISA Kit 96T
E0541Mo Mouse Tumor Specific Growth Facter per tumor supplied group of factor(TSGF)ELISA Kit 96T
E12531854 Mouse Tumor Specific Growth Facter per tumor supplied group of factor(TSGF) ELISA Kit 1
E0540Mo Mouse Tumor Specific Growth Facter-tumor supplied group of factor(TSGF)ELISA Kit 48T
YHB1365Mo Mouse Tumor Specific Growth Facter-tumor supplied group of factor(TSGF)ELISA Kit 48T
EC018 Subcutaneous tumor models
ECR18 Subcutaneous tumor models 1
4-20484 Tumor Dissociation System 4 (Epithelial tumor,Neoplastic, Tumor, islet), Mouse and Rat ea
EH3921 Tumor Specific Growth Facter per Tumor Supplied Group of Factor Elisa Kit 96T
E0771Ra Rat Tumor Specific Growth Facter-tumor supplied group of factor,TSGF ELISA Kit 96T
E0771Ra Rat Tumor Specific Growth Facter per tumor supplied group of factor,TSGF ELISA Kit 48T
E0771Ra Rat Tumor Specific Growth Facter per tumor supplied group of factor,TSGF ELISA Kit 96T
H9548 Tumor Specific Growth Facter tumor supplied group of factor, TSGF, Rat, ELISA Kit 96T
SL0727Ra Rat Tumor Specific Growth Facter tumor supplied group of factor,TSGF ELISA Kit 96T
E0770Ra Rat Tumor Specific Growth Facter-tumor supplied group of factor,TSGF ELISA Kit 48T
E12411965 Rat Tumor Specific Growth Facter per tumor supplied group of factor(TSGF) ELISA Kit 1
YHB1104Ra Rat Tumor Specific Growth Facter-tumor supplied group of factor,TSGF ELISA Kit 96T


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur